12,146 Shares in Zimmer Biomet Holdings Inc (NYSE:ZBH) Bought by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new position in Zimmer Biomet Holdings Inc (NYSE:ZBH) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 12,146 shares of the medical equipment provider’s stock, valued at approximately $1,430,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Private Ocean LLC lifted its position in Zimmer Biomet by 34.8% during the 2nd quarter. Private Ocean LLC now owns 310 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 80 shares in the last quarter. Sound View Wealth Advisors LLC lifted its position in Zimmer Biomet by 2.0% during the 1st quarter. Sound View Wealth Advisors LLC now owns 4,456 shares of the medical equipment provider’s stock worth $569,000 after buying an additional 87 shares in the last quarter. Charter Trust Co. lifted its position in Zimmer Biomet by 5.5% during the 2nd quarter. Charter Trust Co. now owns 1,793 shares of the medical equipment provider’s stock worth $211,000 after buying an additional 93 shares in the last quarter. Motco lifted its position in Zimmer Biomet by 86.2% during the 1st quarter. Motco now owns 216 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 100 shares in the last quarter. Finally, Enlightenment Research LLC lifted its position in Zimmer Biomet by 6.7% during the 1st quarter. Enlightenment Research LLC now owns 1,600 shares of the medical equipment provider’s stock worth $204,000 after buying an additional 100 shares in the last quarter. 88.67% of the stock is owned by hedge funds and other institutional investors.

ZBH has been the topic of several analyst reports. Oppenheimer boosted their price target on shares of Zimmer Biomet from $135.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, July 29th. Sanford C. Bernstein raised shares of Zimmer Biomet from an “underperform” rating to a “market perform” rating and set a $121.71 price target on the stock in a research report on Tuesday, June 11th. Wells Fargo & Co boosted their price target on shares of Zimmer Biomet from $143.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, July 29th. TheStreet cut shares of Zimmer Biomet from a “b-” rating to a “c” rating in a research report on Friday, June 7th. Finally, Credit Suisse Group boosted their price target on shares of Zimmer Biomet from $101.00 to $120.00 and gave the stock an “underperform” rating in a research report on Monday, July 29th. Two analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $141.56.

Shares of ZBH stock traded down $3.47 on Friday, reaching $133.64. The stock had a trading volume of 1,227,611 shares, compared to its average volume of 1,498,252. The company has a quick ratio of 0.56, a current ratio of 1.19 and a debt-to-equity ratio of 0.58. The firm’s 50-day moving average is $130.36 and its two-hundred day moving average is $123.83. The firm has a market capitalization of $28.15 billion, a price-to-earnings ratio of 17.49, a P/E/G ratio of 2.45 and a beta of 1.15. Zimmer Biomet Holdings Inc has a 12 month low of $96.99 and a 12 month high of $140.53.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Friday, July 26th. The medical equipment provider reported $1.93 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.91 by $0.02. The company had revenue of $1.99 billion for the quarter, compared to analysts’ expectations of $1.98 billion. Zimmer Biomet had a negative net margin of 4.56% and a positive return on equity of 13.40%. Zimmer Biomet’s quarterly revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.92 EPS. On average, sell-side analysts forecast that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th were issued a $0.24 dividend. The ex-dividend date of this dividend was Thursday, June 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.72%. Zimmer Biomet’s payout ratio is 12.57%.

In other news, VP Chad F. Phipps sold 32,800 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $140.00, for a total value of $4,592,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.72% of the stock is currently owned by corporate insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Recommended Story: How does a reverse stock split work?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.